Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 11/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1339339 | 0.85 | HCRTR1 (0.52) | HCRTR1HCRTR2CYP2C9CYP2C19 | |
| SCHEMBL1398589 | 0.83 | HCRTR1 (0.49) | HCRTR1HCRTR2POLBLMNAHPGD | |
| SCHEMBL1340002 | 0.79 | HCRTR1 (0.54) | HCRTR1HCRTR2LMNAHPGDALDH1A1 | |
| SCHEMBL1339152 | 0.79 | HCRTR1 (0.58) | HCRTR1HCRTR2 | |
| SCHEMBL2930343 | 0.78 | HCRTR1 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL1339577 | 0.78 | HCRTR1 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL2930345 | 0.78 | HCRTR1 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL2932952 | 0.75 | LMNA (0.47) | POLBLMNAHPGDMEN1KMT2A | |
| SCHEMBL3430439 | 0.75 | LMNA (0.47) | POLBLMNAHPGDMEN1KMT2A | |
| SCHEMBL1339871 | 0.74 | HCRTR1 (0.76) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063099-B2 | Trans-3-aza-bicyclo[3.1.0]hexane derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-11-22 | — | — | US | disclosed |
| US-20100204285-A1 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204285-A1 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | HCRTR1, HCRTR2, CNR1 | HCRTR1 1/4885HCRTR2 2/4885POLB 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.